Various Procedural Treatment Options for Androgenetic Alopecia
ConditionAndrogenetic Alopecia
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexMale
Age20-50
SponsorSheikh Zayed Medical College
About this trial
Androgenetic alopecia (AGA)is the most common form of alopecia. It predominantly affects males, but there has been a significant surge in female preponderance too, over the last decade Minoxidil belong to the anti-hypertensive class but it also affects the potassium channels present in vascular smooth muscles and hair follicles. This potassium channel activity may stimulate the microcirculation around the hair follicles and induces arteriolar vasodilation, thereby encouraging conditions conducive to hair growth Topical administration of finasteride offers the potential to reduce systemic effects related to its mechanism of action by preferentially inhibiting 5-a reductase in the scalp, as has been suggested in recent years so in this study we are going to compare efficacy of topical minoxidil versus topical finasteride in treatment of androgenetic alopecia
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age: 20-50 years
Gender: Male
ANDROGENETIC ALOPECIA with AGA stage 2-6 Norwood-Hamilton -classification
Patients not taking any treatment in last 1 month
Disqualifiers
Abrasion or abnormalities to the scalp
Hair transplant
Hypersensitivity
Recent history of local infections of the head
Trial design
Design model
Parallel
Treatments tested in this trial
topical finasteride
DrugGroup A will receive topical finesteride spray 0.25% twice daily for 12 weeks
Topical minoxidil
DrugGroup B will receive topical 5% minoxidal twice daily for 12 weeks
Treatment groups
190 Participants
are divided into 2 treatment groupsGroup A: Finesteride groupActive comparator 1 intervention
Group B: Minoxidil groupActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
COMPARISON OF EFFICACY OF TOPICAL FINESTERIDE VERSUS TOPICAL MINOXIDAL IN TREATMENT OF ANDROGENETIC ALOPECIA
The final efficacy will be divided into following groups on the basis of Norwood-Hamilton scale from the baseline :1.Excellent efficacy: It is defined as greater than two scale change in hair density as measured from baseline . 2. moderate efficacy : It is defined as one to two scale change in hair density as measured from baseline. Percentage increase in hair density as clinically measured by the surface area from the baseline. 3.Non efficacious: It is defined as less than one scale change in hair density as measured clinically from baseline.
Time frame
Clinical assessment for efficacy will be done monthly for 6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: